Premium
Pharmacokinetics of guanazole in patients with acute myelocytic leukemia
Author(s) -
Dave Chandrakant,
Higby Donald,
Mattern John,
Holland James F.,
Grace J. T.
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt197517136
Subject(s) - pharmacokinetics , volume of distribution , plasma clearance , myelocytic leukemia , distribution volume , distribution (mathematics) , renal function , medicine , pharmacology , acute leukemia , drug , chemistry , urology , leukemia , mathematical analysis , mathematics
Levels of guanazole (GZ) in plasma and packed cells were determined after a single tracer dose of 14 C‐guanazole or during a 5‐day continuous intravenous therapeutic infusion of unlabeled drug to 5 patients with acute myelocytic leukemia (A ML). The levels of unlabeled drug were determined colorimetrically. GZ injected as a tracer dose was rapidly distributed in an apparent volume of 0.61/kg, which is somewhat less than that of total body water, and the drug appeared to be eliminated essentially unchanged by glomerular filtration. The mean apparent volume of distribution increased by about 15% during infusion. An increase of 60% was also noted in the half‐life (t ½ ) values, with a concomitant decrease in the mean value of renal clearance rate by 40%, except in 1 case. The study demonstrates that monitoring levels of guanazole is possible during infusion therapy and indicates that the data could be used to evaluate pharmacokinetic parameters predicting the time‐course of such levels in patients.